secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001213900-22-011579
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points
--------------------------------------------------------------------------------

- Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.
- FY2021 net loss $12.4M ($1.13/share) vs $5.9M ($1.37/share) in FY2020; R&D expense rose to $7.6M.
- RADR AI platform grew from 1.2B to over 18B data points during 2021; target of 25B by end 2022.
- LP-300 Phase 2 Harmonic trial for never-smoker NSCLC expected to launch in 2022; LP-184 multiple Phase 1 trials in 2022.
- LP-184 received Orphan Drug Designations for pancreatic cancer, GBM, ATRT; Rare Pediatric Disease Designation for ATRT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022011579/0001213900-22-011579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022011579/ea156639-8k_lantern.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-011579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer